The U.S. Food and Drug Administration on 10/10/14 approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection.
“Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection. It is also the first approved regimen that does not require administration with interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection.”
Full FDA press release –includes data supporting approval.
Related blog post: The Future is Now (for Hepatitis C) | gutsandgrowth
gutsandgrowth 
Pingback: Telaprevir-Based HCV Therapy is Expensive Too | gutsandgrowth
Pingback: Clinical Science Year in Review in Pediatric GI – NASPGHAN 2014 | gutsandgrowth
Pingback: Financial Relief For Patients with Hepatitis C | gutsandgrowth
Pingback: Hepatitis C : New and Newer Treatments | gutsandgrowth
Pingback: Changing Narrative on Affordability of HCV Treatments | gutsandgrowth